Pfizer CFO Change Tests Market Confidence
from The Daily News Now! Business
Pfizer’s stock tumbled 2.74% today after announcing a CFO change, sparking investor concern over its 2026 financial targets—especially revenue and EPS—amid a backdrop of recent drug approvals and rising market scrutiny. While the broader market rose, peers like Merck and Bristol-Myers Squibb also fell, highlighting sector-wide caution. With high trading volume, investors are demanding clear guidance on how new products and cost-cutting will drive earnings, testing Pfizer’s ability to maintain confidence during this leadership transition. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/9b3dfaeffb510024
Embed this episode
No transcript yet.